YTHDF1 and neoplasm: Although YTHDF1 expression showed no significant differences at different stages both in TCGA and the GSE29272 dataset, GC patients in late stages (FIGO stage III or IV) rather than in early stages (FIGO stage I or II) with high YTHDF1 expression tended to exhibit poor survival and tumor recurrence (Figure 1F and Supplementary Figures S2A–C).